The announcement of the pending departure of Tyson Foods CEO Donnie Smith coupled with the company's forecast that profits for FY 2017 would be lower that previously stated, sent the meat processor's shares downward on Monday.
EFSA found the available literature investigating the effects of the feed additive, zilpaterol, on animal health and welfare is limited but indicates a potential increase in mortality, heart rate, respiration rate and agonistic behavior in cattle.
The question of if or when Zilmax will return to the US market remains unanswered despite recently published research into fatigue cattle syndrome and use of beta-agonists showing the cause to be ‘multifactorial’.
Zilmax maker Merck says it has not made any decision to resume sales of the cattle additive in the US as a campaign group there condemns the company for “taking steps” to put the beta agonist back on the market.
Cargill said it still has no intention of taking cattle fed Zilmax back into its supply chain, despite Merck saying its research has shown the beta-agonist, pulled from the market last year due to concerns over side effects, is safe.